Several Points from CC: 1) 60k booked from Sou
Post# of 405
(Total Views: 2559)
Posted On: 05/13/2017 11:23:47 PM
Several Points from CC:
1) 60k booked from South Korea from Zestra 3-packs. Will be shipping Zestra multi-dose soon as this will be their second purchase order so far in 2017. Confirmed $2M is minimum and expects to hit it.
2) From here on out (for 2017) another 6-7 new product launches are to take place. Goal is to have 25 products by year end...currently we have 18. Keep in mind NONE of these were in the 15M guidance that came from that Q4 conf call. This is a big deal because the sooner more products launch - the more sales revenue that will get booked for 2017.
3) Overseas distribution deals go straight to their bottom line - no extra marketing expense for them to show. Get the sense we should hear something very soon
4) Only used 496k of cash...that was awesome. NO convertibles on the books - NONE. so the $3.3M Net from offering went to them and they took 1.3M of that to knock out convertibles. 2M left plus cash on hand less the 496k used = $2.4M of current cash on hand. Approx $3.8M more could flow in from 1 yr warrants and ANOTHER $3.8M from the 5 yr warrants, when exercised.
5) No special requirements from Hikma deal...min purchase orders. When I logically think about it, I keep coming to the conclusion that they believe in INNV and bought the offering. Quite sure Hoffman came on board to orchestrate the deal. (MY OPINION) The documents should show the buyer as it's clearly more than a 10%+ owner. Excited to find out who owns the 25M shares and 50M warrants. Bet it's an Investment Bank as usually they buy/hold for a BIG GUN and it's listed under them.
6) BH Canada is coming as well as other sales channels so stay tuned.
** Clearly, we should expect a PR about Viagra/Vesele study which should be a great catalyst for Vesele sales. We should expect approx 6-7 new product launches and at least 2-3 more overseas distribution deals - very healthy for our bottom line. Exiting 2017 PROFITABLE is still a MAJOR MILESTONE. Repeated 4 times during call
- Again, I am Underwhelmed with Q1 revenue but excited about profitability talk as they are aware that cost reduction is key. Fluti launching in Q4 and they want to do it right. Big on the subscription model in which clients get it automatically shipped each month. I think we get a nasal rinse soon and a migraine solution too. GLTY
12.5-14M is a lock for 2017 revenue....no doubt in my mind.
We were trading 7 cents on 1m in revs and 49M o/s
So, what would 12.5M in revs with 221M o/s look like ?
12.5 x 7 Divided by 4.5 = .1944 PPS. YOU DECIDE
** SPIN - hope this answers your dilution question...using 221M and we are at 150.53M o/s today
1) 60k booked from South Korea from Zestra 3-packs. Will be shipping Zestra multi-dose soon as this will be their second purchase order so far in 2017. Confirmed $2M is minimum and expects to hit it.
2) From here on out (for 2017) another 6-7 new product launches are to take place. Goal is to have 25 products by year end...currently we have 18. Keep in mind NONE of these were in the 15M guidance that came from that Q4 conf call. This is a big deal because the sooner more products launch - the more sales revenue that will get booked for 2017.
3) Overseas distribution deals go straight to their bottom line - no extra marketing expense for them to show. Get the sense we should hear something very soon
4) Only used 496k of cash...that was awesome. NO convertibles on the books - NONE. so the $3.3M Net from offering went to them and they took 1.3M of that to knock out convertibles. 2M left plus cash on hand less the 496k used = $2.4M of current cash on hand. Approx $3.8M more could flow in from 1 yr warrants and ANOTHER $3.8M from the 5 yr warrants, when exercised.
5) No special requirements from Hikma deal...min purchase orders. When I logically think about it, I keep coming to the conclusion that they believe in INNV and bought the offering. Quite sure Hoffman came on board to orchestrate the deal. (MY OPINION) The documents should show the buyer as it's clearly more than a 10%+ owner. Excited to find out who owns the 25M shares and 50M warrants. Bet it's an Investment Bank as usually they buy/hold for a BIG GUN and it's listed under them.
6) BH Canada is coming as well as other sales channels so stay tuned.
** Clearly, we should expect a PR about Viagra/Vesele study which should be a great catalyst for Vesele sales. We should expect approx 6-7 new product launches and at least 2-3 more overseas distribution deals - very healthy for our bottom line. Exiting 2017 PROFITABLE is still a MAJOR MILESTONE. Repeated 4 times during call
- Again, I am Underwhelmed with Q1 revenue but excited about profitability talk as they are aware that cost reduction is key. Fluti launching in Q4 and they want to do it right. Big on the subscription model in which clients get it automatically shipped each month. I think we get a nasal rinse soon and a migraine solution too. GLTY
12.5-14M is a lock for 2017 revenue....no doubt in my mind.
We were trading 7 cents on 1m in revs and 49M o/s
So, what would 12.5M in revs with 221M o/s look like ?
12.5 x 7 Divided by 4.5 = .1944 PPS. YOU DECIDE
** SPIN - hope this answers your dilution question...using 221M and we are at 150.53M o/s today
(1)
(0)Innovus Pharmaceuticals Inc. (INNV) Stock Research Links
Scroll down for more posts ▼